S&P 500 Analysis & ETF Trading

[kiy]

RNN

Thanks, RNN is another one worth watching/tracking...
I-Hub not letting me make any edits on the Intro page...maybe tomorrow can adjust the charts on the speculation stocks...

http://seekingalpha.com/article/1947711-rexahn-pharmaceutical-shares-are-still-a-buy-despite-recent-volatility
While the surge was great news for long-term investors and those that got early into the rally more than a week ago, and also cancer patients, the question for potential investors on the sidelines is whether one should get into Rexahn at these levels, after shares more than quadrupled nadir-to-zenith in just the last month. In that context, does the current pullback over the last two days offer another opportunity for long-term investors to get in at a discount price, or was it a 'sucker rally' with the current decline being not an opportunity but a 'bull trap'? We will try to answer this question in the rest of the article by examining Rexahn's development pipeline and the potential it holds for investors.

Rexahn has a lot of things going for it. It has one of the broadest pipeline of drugs (see chart) that we have seen among micro-cap biotech companies, targeting a wide variety of cancer indications, with each of them targeting using a different mechanism of action.
Rexahn has received the U.S. FDA Orphan Drug Designation for Archexin for renal cancer as well as four other cancers including pancreatic cancer, ovarian cancer, glioblastoma and stomach cancer. An orphan drug designation in the U.S. is targeted at promoting drug therapies for diseases and conditions that affect fewer than 200,000 people, and is awarded with benefits such as seven year market exclusivity in the U.S., an accelerated review process, and tax advantages, as an incentive to encourage drug development in indications that otherwise lack a sufficient profit motive. The targeted indications for Archexin, besides being orphan diseases, also are among the most lethal types of cancer. For example, pancreatic cancer has a five-year mortality rate of 94%, stomach cancer 72%, glioblastoma 67%, ovarian cancer 56%, and kidney cancer 28% vs. the more common cancers such as skin, breast and prostate that have mortality rates of 9%, 11% and 1% respectively

We believe that the current low price is reflective of a number of things, including that the company has traded in penny stock category for the last two years, that it has only recently narrowed its focus to the oncology space that now makes it easier to value the company, and that most of its pipeline until recently was preclinical. However, things are changing now, and the stock has begun to reflect some of the upside. On a technical basis, however, the stock looks very dicey here, and we would at best only dip our toe in here, taking a small starter position, and building it as the stock consolidates and say falls into its earlier resistance area in the $0.80 to $0.90 range.
We should also mention here that as we finish writing this, the company announced Wednesday morning a $20 mill. registered direct offering at $1.05 per unit, with each unit including one share of common stock and a five year warrant to purchase 0.25 of a share of common stock at an exercise price of $1.28 per share. The placement agent Roth Capital Partners, incidentally also had a bullish note on the stock last week after Wednesday's announcement, reiterating a buy and raising its price target to $3, well above current prices in the $1 range.

I'm going to test an 8average on the OBV daily...from the usual 10day...